Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Short-term Investments (2023 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Short-term Investments for 3 consecutive years, with $55.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short-term Investments changed 0.0% year-over-year to $55.0 million, compared with a TTM value of $55.0 million through Sep 2025, changed 0.0%, and an annual FY2024 reading of $55.0 million, changed 0.0% over the prior year.
  • Short-term Investments was $55.0 million for Q3 2025 at Arcturus Therapeutics Holdings, roughly flat from $55.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $55.0 million in Q4 2023 and bottomed at $55.0 million in Q4 2023.
  • Average Short-term Investments over 3 years is $55.0 million, with a median of $55.0 million recorded in 2023.
  • Peak annual rise in Short-term Investments hit 0.0% in 2024, while the deepest fall reached 0.0% in 2024.
  • Year by year, Short-term Investments stood at $55.0 million in 2023, then changed by 0.0% to $55.0 million in 2024, then changed by 0.0% to $55.0 million in 2025.
  • Business Quant data shows Short-term Investments for ARCT at $55.0 million in Q3 2025, $55.0 million in Q2 2025, and $55.0 million in Q4 2024.